Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Travis Kelce responds to Jana Kramer's claims he's a bad influence on girlfriend Taylor SwiftWould YOU spend £109 on nonHideki Matsuyama withdraws from Wells Fargo Championship before 1st round with a back injuryThe REAL reason no one should have to pay for their prescriptionsFIFA urged to review congested calendar or face legal action from player unions and leaguesNelly Korda shoots 69 to put herself in position for a recordUS utility pledges more transparency after lack of notice it empowered CEO to make plant decisionsJohn Leguizamo reveals he TURNED DOWN Stanley Tucci's role in The Devil Wears PradaBungalow wars! Downsizers are in bidding battles against young families as prices soarGovernor says he won't support a bill that could lead to $3M in assistance to striking workers